Navigation Links
Susan G. Komen for the Cure Launches Unprecedented Global Expansion Program in 10 Countries
Date:9/29/2007

he global expansion program with $3 million in this first phase alone. The modules have been adapted for cultural sensitivity in each country and will develop into institutional knowledge that will be sustainable long into the future. A few other countries will be announced shortly.

"Public education and awareness initiatives lead to earlier breast cancer detection, when the disease is most treatable," said Ambassador Nancy G. Brinker, founder of Susan G. Komen for the Cure. "Susan G. Komen for the Cure's experience over the past 25 years funding education, screening, treatment and advocacy grants in more than 50 countries has demonstrated the positive impact grassroots outreach has on saving women's lives. Now it is time to move beyond grants and help create infrastructures around the world that can further the global breast cancer movement and save more lives." The countries were selected in collaboration with the State Department, based on data from the World Health Organization and information from Komen's grant funding in more than 50 countries. Komen has tapped the Institute of International Education to be the implementing partner in this program.

"We want to share the practices we have developed and implemented over the past 25 years in the U.S. with nations where breast cancer advocacy, training and awareness are still in its infancy," said Hala Moddelmog, president and CEO of Susan G. Komen for the Cure. "We recognize that in many of the pilot countries people are still struggling with basic health needs. However, the 10 countries participating in this effort are already making strides in breast cancer awareness and outreach, have economic and political environments favorable to success and are seeking to bring breast cancer to their local and national policy agendas. We will support their efforts through funding and sharing proven outreach strategies as well as co-producing knowledge that will save lives."

The announcement was made durin
'/>"/>

SOURCE Susan G. Komen for the Cure
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Glaxo launches pills to help smokers quit in 7-12 weeks
2. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
3. Dr Reddy’s Laboratories launches Hyalosy
4. Serum Institute Launches New Tetanus-Diphtheria Vaccine
5. Scottish Health Minister Launches Organ Donor Plan
6. GlaxoSmithKline launches diabetes and cancer drugs
7. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
8. Pfizer Launches Viagra For Lung Disease In UK
9. PM Launches Healthcare Foundation For India
10. African Union Launches A Programme On Acceleration of HIV Prevention
11. Yale School of Medicine Launches Telemonitoring Of Heart Failure Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:LCA-Vision's National Lasik Network Named as U.S. Provider for National Vision Administrators 2Health News:LCA-Vision's National Lasik Network Named as U.S. Provider for National Vision Administrators 3Health News:LCA-Vision's National Lasik Network Named as U.S. Provider for National Vision Administrators 4Health News:WuXi AppTec Successfully Holds Its 2009 Supplier Conference in Shanghai 2Health News:WuXi AppTec Successfully Holds Its 2009 Supplier Conference in Shanghai 3Health News:New Occupational Therapy School and Career Resource on All Allied Health Schools 2Health News:New Occupational Therapy School and Career Resource on All Allied Health Schools 3Health News:Compass Pharma Services Offers Microfill Capabilities to Contract Pharmaceutical Packaging Customers 2Health News:Helping to Clear the Air for Consumers - New Certification Standard for HEPA Filters Will Help Millions of People Make More Educated Choices 2Health News:Official Launch of ABLE TO CHOOSE Public Awareness Campaign 2
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Senator Durbin Leads Fight to Protect Americas Kids from Tobacco 48681 1Senator Durbin Leads Fight to Protect Americas Kids from Tobacco 48681 2Senator Durbin Leads Fight to Protect Americas Kids from Tobacco 48681 3Herley Industries Inc Reports Third Quarter Earnings 48677 1Herley Industries Inc Reports Third Quarter Earnings 48677 2Herley Industries Inc Reports Third Quarter Earnings 48677 3Herley Industries Inc Reports Third Quarter Earnings 48677 4Herley Industries Inc Reports Third Quarter Earnings 48677 5Herley Industries Inc Reports Third Quarter Earnings 48677 6Herley Industries Inc Reports Third Quarter Earnings 48677 7Herley Industries Inc Reports Third Quarter Earnings 48677 8Herley Industries Inc Reports Third Quarter Earnings 48677 9Herley Industries Inc Reports Third Quarter Earnings 48677 10Herley Industries Inc Reports Third Quarter Earnings 48677 11Herley Industries Inc Reports Third Quarter Earnings 48677 12Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer All Claims Denied 48673 1Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer All Claims Denied 48673 2